🔗 Share this article

Given that the United States undertakes unprecedented changes to its immunization guidelines, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by questioning COVID-19 vaccines in the global health crisis and has focused upon possible fatalities after COVID-19 vaccination in her short tenure at the FDA.

Scheduled Overhauls to Childhood Vaccine Schedule

Health officials had intended to reveal radical revisions to the childhood vaccine schedule in December, synchronizing the US with the Danish vaccine program, sources say – a significant shift that would place the US out of step with many the world with insufficient data for benefit. The announcement has been delayed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to head the office this year.

A New Direction at the Agency

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon reevaluating already-approved immunizations at the FDA.

Høeg has repeatedly called for ending certain childhood vaccine recommendations in the US to become more like Denmark, a society with nationalized medicine and a population about the population of Wisconsin’s.

So far comments, she has kept her attention on vaccines – typically the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Concerns Over Expertise

Høeg has no apparent track record in drug development, regulation or leadership, which has been standard for past heads of the CBER. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“She appears not to have the necessary background” for leading the CDER, stated Dr. Jonathan Howard. “She’s never run a scientific study. She lacks experience in leading a large organization. She lacks background in drug approvals.”

Past heads of the center would “be deeply familiar with laws and regulations and the science of drug development”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that prior appointees who headed CBER have had.”

CDER has an immense workload at the agency, she stated.

“Everybody just pays attention on the new drug program, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and so forth, and each of these must be supervised,” she noted. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant management element to the job, which manages over 5,000 personnel. “It’s a massive administrative position, if you do it right,” she concluded.

Agency Reaction and Disputed Initiatives

Regarding concerns about Høeg’s credentials and whether this selection represents increased cooperation among FDA leaders on immunizations, a press secretary said that the “inquiries rely on inaccurate assumptions”.

“Her resume aligns with the duties of her role,” the spokesperson said, pointing to the time Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched expedited review system, a contentious one-day medication authorization process that allegedly concerned her preceding directors. “By what process are these therapies being picked for this expedited pathway? Who takes the calls?” Dr. Howard asked. “There is a lot of secrecy going on at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards laxer oversight of most medications, aside from shots.”

Established History on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if concerning, history, critics said. She released a analysis using unverified volunteer-provided data to estimate the incidence of myocarditis after Covid vaccination. She counseled the Florida surgeon general Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are riskier than they are.

Among her “policy goals” for the current administration included altering rules for novel immunizations and halting “unnecessary” vaccines, she said after the election on a podcast. At the agency, Dr. Høeg has according to sources proposed preventing adolescent males from getting COVID-19 vaccinations.

“She’s an complete ideologue who begins with her beliefs and works backwards to fit the science in a extremely disingenuous, untruthful manner,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|